Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BioCryst

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Tuesday agreed to acquire Astria Therapeutics, Inc. (NASDAQ:ATXS) for a mix of cash and stock.

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB). The regulatory agency has granted Priority Review designation and assigned a target actin date of February 17,…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

BioCryst's Voluntary Pause Of Rare Blood Disorder Trial Turns Into FDA Clinical Hold

Tucked in its Q1 earnings release, a voluntary pause for BioCryst Pharmaceuticals Inc's (NASDAQ:BCRX) complement-mediated disease therapy has been upgraded to a partial FDA clinical hold. The update clarified why the company paused trials testing BCX9930 in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare disorder marked by the destruction of red blood cells…

Oppenheimer Maintains Outperform Rating for BioCryst Pharmaceuticals, Lowers Price Target To $16

Oppenheimer has decided to maintain its Outperform rating of BioCryst Pharmaceuticals (NASDAQ:BCRX) and lower its price target from $20.00 to $16.00. Shares of BioCryst Pharmaceuticals are trading down 1.62% over the last 24 hours, at $10.94 per share.

Read Here Why Did BioCryst Stopped Enrollment In BCX9930 Studies In Rare Blood Disorder

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) has paused enrollment in clinical trials with BCX9930 as the Company investigates elevated serum creatinine levels seen in some patients. The Company will not enroll new patients in the REDEEM-1, REDEEM-2, or RENEW clinical trials during the investigation. Patients currently enrolled in the trials are continuing on the study…

BioCryst's Orladeyo Shows Long Term Benefit With Sustained Reductions in Attack Rates

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX)

inkl

Read news from The Economist, FT, and more,
with one subscription

Is BioCryst (BCRX) Ready to Breakout to New Highs on Recent Catalysts?

Is BioCryst (BCRX) Ready to Breakout to New Highs on Recent Catalysts?

By Ben Rabizadeh – Fundamentals well positioned with $1B peak sales forecast for Orladeyo and $300M influx of cash from royalty deals – Potential catalysts: update on Orladeyo sales with Q4 results on Feb. 23; BCX9930 trial enrollment underway and expect updates on progress

Organisations

European Medicines Agency

Jazz Pharmaceuticals

Medicines and Healthcare products Regulatory Agency

BridgeBio Pharma

BioCryst Pharmaceuticals

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

327,002 stories

128,218 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play